Table 1.
Summary of patient characteristics
| Group A | Group B | P | |
|---|---|---|---|
| (n = 27) | (n = 26) | ||
| Sex | |||
| Male | 16 (59%) | 14 (53%) | |
| Female | 11 (41%) | 12 (47%) | 0.74 |
| Onset age | |||
| < 45 | 16 (59%) | 12 (46%) | |
| > 45 | 11 (41%) | 14 (54%) | 0.26 |
| Pre-surgery KPS | |||
| 60–80 | 5 (18%) | 6 (23%) | |
| > 80 | 22 (82%) | 20 (77%) | 0.42 |
| Brain lobes involved in tumor | |||
| 1 | 14 (52%) | 15 (57%) | |
| > 1 | 13 (48%) | 11 (43%) | 0.42 |
| MGMT methylation | |||
| Yes | 12 (44%) | 14 (54%) | |
| No | 13 (48%) | 10 (38%) | |
| Unknown | 2 (8%) | 2 (8%) | 0.78 |
| IDH mutation | |||
| Mutated | 5 (18.5%) | 8 (31%) | |
| Wild type | 17 (63%) | 12 (46%) | |
| Unknown | 5 (18.5%) | 6 (23%) | 0.14 |
| TMZ therapeutic cycles | |||
| 6 | 27 (100%) | 0 | |
| 7–9 | 10 (38%) | ||
| 10–12 | 9 (34%) | ||
| > 12 | 7 (28%) | < 0.001 | |
| Total patient number | 27 | 26 | 53 |